Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Isakoff, S. J.
Right arrow Articles by Brugge, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isakoff, S. J.
Right arrow Articles by Brugge, J. S.
[Cancer Research 65, 10992-11000, December 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells

Steven J. Isakoff1,3, Jeffrey A. Engelman2,4,5, Hanna Y. Irie1,3, Ji Luo2,5, Saskia M. Brachmann2,5, Rachel V. Pearline1, Lewis C. Cantley2,5 and Joan S. Brugge1

Departments of 1 Cell Biology and 2 Systems Biology, Harvard Medical School; 3 Department of Medical Oncology, Dana-Farber Cancer Institute; 4 Massachusetts General Hospital Cancer Center; and 5 Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Requests for reprints: Joan S. Brugge, Department of Cell Biology, Harvard Medical School, Building C, Room 513, 240 Longwood Avenue, Boston, MA 02115. Phone: 617-432-3973; Fax: 617-432-3969; E-mail: joan_brugge{at}hms.harvard.edu.

Activation of the phosphoinositide 3-kinase (PI3K) pathway has been implicated in the pathogenesis of a variety of cancers. Recently, mutations in the gene encoding the p110{alpha} catalytic subunit of PI3K (PIK3CA) have been identified in several human cancers. The mutations primarily result in single amino acid substitutions, with >85% of the mutations in either exon 9 or 20. Multiple studies have shown that these mutations are observed in 18% to 40% of breast cancers. However, the phenotypic effects of these PIK3CA mutations have not been examined in breast epithelial cells. Herein, we examine the activity of the two most common variants, E545K and H1047R, in the MCF-10A immortalized breast epithelial cell line. Both variants display higher PI3K activity than wild-type p110{alpha} yet remain sensitive to pharmacologic PI3K inhibition. In addition, expression of p110{alpha} mutants in mammary epithelial cells induces multiple phenotypic alterations characteristic of breast tumor cells, including anchorage-independent proliferation in soft agar, growth factor–independent proliferation, and protection from anoikis. Expression of these mutant p110{alpha} isoforms also confers increased resistance to paclitaxel and induces abnormal mammary acinar morphogenesis in three-dimensional basement membrane cultures. Together, these data support the notion that the cancer-associated mutations in PIK3CA may significantly contribute to breast cancer pathogenesis and represent attractive targets for therapeutic inhibition.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. J. Crowder, C. Phommaly, Y. Tao, J. Hoog, J. Luo, C. M. Perou, J. S. Parker, M. A. Miller, D. G. Huntsman, L. Lin, et al.
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
Cancer Res., May 1, 2009; 69(9): 3955 - 3962.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. P. Gustin, B. Karakas, M. B. Weiss, A. M. Abukhdeir, J. Lauring, J. P. Garay, D. Cosgrove, A. Tamaki, H. Konishi, Y. Konishi, et al.
Knockin of mutant PIK3CA activates multiple oncogenic pathways
PNAS, February 24, 2009; 106(8): 2835 - 2840.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Di Nicolantonio, S. Arena, M. Gallicchio, D. Zecchin, M. Martini, S. E. Flonta, G. M. Stella, S. Lamba, C. Cancelliere, M. Russo, et al.
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
PNAS, December 30, 2008; 105(52): 20864 - 20869.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, et al.
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Cancer Res., November 15, 2008; 68(22): 9221 - 9230.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. L. Yuan, H. S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J. V. Frangioni, and L. C. Cantley
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
PNAS, July 15, 2008; 105(28): 9739 - 9744.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Zhao and P. K. Vogt
Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
PNAS, February 19, 2008; 105(7): 2652 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ocana and A. Pandiella
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel
The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations
Science, December 14, 2007; 318(5857): 1744 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas
Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Costa, L. Barberis, C. Ambrogio, A. D. Manazza, E. Patrucco, O. Azzolino, P. O. Neilsen, E. Ciraolo, F. Altruda, G. D. Prestwich, et al.
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase {gamma}
PNAS, September 4, 2007; 104(36): 14354 - 14359.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Larsson, S. Li, O. A. Issaenko, S. Avdulov, M. Peterson, K. Smith, P. B. Bitterman, and V. A. Polunovsky
Eukaryotic Translation Initiation Factor 4E Induced Progression of Primary Human Mammary Epithelial Cells along the Cancer Pathway Is Associated with Targeted Translational Deregulation of Oncogenic Drivers and Inhibitors
Cancer Res., July 15, 2007; 67(14): 6814 - 6824.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
N. Miled, Y. Yan, W.-C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer, and R. L. Williams
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Science, July 13, 2007; 317(5835): 239 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-N. Guo, A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski, C. LeVea, R. M. Hoffman, M. G. Brattain, and J. Wang
Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model
Cancer Res., June 15, 2007; 67(12): 5851 - 5858.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt
Rare cancer-specific mutations in PIK3CA show gain of function
PNAS, March 27, 2007; 104(13): 5569 - 5574.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Schmelzle, A. A. Mailleux, M. Overholtzer, J. S. Carroll, N. L. Solimini, E. S. Lightcap, O. P. Veiby, and J. S. Brugge
Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis
PNAS, March 6, 2007; 104(10): 3787 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman
Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA
Mol. Cell. Biol., January 15, 2007; 27(2): 662 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. J. Zhao and T. M. Roberts
PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target
Sci. Signal., December 12, 2006; 2006(365): pe52 - pe52.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia.
Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Overholtzer, J. Zhang, G. A. Smolen, B. Muir, W. Li, D. C. Sgroi, C.-X. Deng, J. S. Brugge, and D. A. Haber
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon
PNAS, August 15, 2006; 103(33): 12405 - 12410.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.